Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to adequate sedation (minutes or as measured by specific validated scales such as the Ramsay Sedation Score) · children undergoing neurodiagnostic procedures
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (high certainty).
1 finding from 1 review
Functional outcomes · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Hypoglycaemic episodes
It is very uncertain whether insulin glargine changes hypoglycaemic episodes(1) Severe hypoglycaemia (2) Serious… compared with NPH insulin (very low certainty).
1 finding from 1 review
Hypoglycaemic episodes
It is very uncertain whether insulin detemir changes hypoglycaemic episodes (1) Severe hypoglycaemia (2) Serious… compared with NPH insulin (very low certainty).
1 finding from 1 review
RR 0.45 [0.17, 1.2]
1 study · 5 participants
Very low
Failure to induce clinical remission at end of study · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve clinical remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical response · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to maintain clinical response (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve endoscopic remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
0.05 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
0.05 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
0.05 mg/d · participants with normal or abnormal lipid profiles
1 finding from 1 review
QoL · people with CAH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevention of adrenal crisis · people with CAH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found